Article
Precise and efficient silencing of mutant KrasG12D by CRISPR-CasRx controls pancreatic cancer progression.
Theranostics - 1 Jan 2020
Jiang Wang, Li Hao, Liu Xiyu, Zhang Jianping, Zhang Wuhu, Li Tianjiao, Liu Liang, Yu Xianjun
Abstract excerpt
Rationale: Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal disease with few therapeutic targets and rare effective treatments. Over 90% of PDAC tumors bear a Kras mutation, and the single-site mutation G12D (KrasG12D) is most prevalent. Methods: Here, we applied the CRISPR-CasRx system to silence the mutant KrasG12D transcript in PDAC cells. We also used a capsid-optimized adenovirus-associated virus 8...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.